SCHEMBL94929

SCHEMBL94929

O=[C]c1c(Cl)cc(Cl)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.45
TSHR P16473 5/20 0.41
HSD17B10 Q99714 5/20 0.41
CYP3A4 P08684 3/20 0.41
RECQL P46063 3/20 0.41
HPGD P15428 3/20 0.36
AHR P35869 1/20 0.36
TP53 P04637 2/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA9 Q16790 1/20 0.34
AKR1C4 P17516 1/20 0.34
AKR1C3 P42330 1/20 0.34
AKR1C2 P52895 1/20 0.34
AKR1C1 Q04828 1/20 0.34
ERN1 O75460 1/20 0.34
GPR35 Q9HC97 1/20 0.34
KDM4E B2RXH2 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10704960 0.78 ERN1 (0.41) ALDH1A1CYP3A4HPGDERN1KDM4E
SCHEMBL11593707 0.74 TSHR (0.37) ALDH1A1TSHR
SCHEMBL7308747 0.72 ALDH1A1 (0.43) ALDH1A1CYP3A4HPGDCA1CA2
SCHEMBL9712347 0.72 TSHR (0.35) TSHR
SCHEMBL1312705 0.72 CYP3A4 (0.50) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL3859125 0.71 ALDH1A1 (0.45) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL1312947 0.71 CYP3A4 (0.47) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL952362 0.71 ALDH1A1 (0.45) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL18245265 0.71 ALDH1A1 (0.45) ALDH1A1TSHRHSD17B10CYP3A4RECQL
SCHEMBL96213 0.71 CYP1A2 (0.43) ALDH1A1TSHRMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE48335-E1 Polymyxin derivatives as antimicrobial compounds MONASH UNIVERSITY (AU) 2020-12-01 US claimed
CN-106414480-B Polymyxin derivatives as antimicrobial compounds 莫纳什大学 2020-08-04 CN claimed
EP-2595948-B1 A METHOD OF PRODUCING INGENOL-3-ANGELATE LEO LABORATORIES LTD (IE) 2019-09-04 EP claimed
EP-3106477-B1 (METH)ACRYLIC ACID ESTER COMPOUND AND PRODUCTION METHOD THEREFOR MITSUBISHI GAS CHEMICAL CO (JP) 2018-08-29 EP claimed
US-20170137469-A1 POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS MONASH UNIVERSITY (AU) 2017-05-18 US claimed
CN-106414480-A POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS 莫纳什大学 2017-02-15 CN claimed
EP-3126376-A1 POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS Monash University (AU) 2017-02-08 EP claimed
EP-2662376-B1 PROCESS FOR PREPARING TORISEL TIANJIN WEIJIE TECHNOLOGY CO LTD (CN) 2016-11-30 EP claimed
US-9234087-B2 Preparation for initiating radical reactions UNITED INITIATORS GMBH & CO. KG (DE) 2016-01-12 US claimed
WO-2015149131-A1 POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS MONASH UNIVERSITY (AU) 2015-10-08 WO claimed
EP-1556369-A1 PYRIDAZINONE-DERIVATIVES AS PDE4 INHIBITORS ALTANA Pharma AG (DE) 2005-07-27 EP claimed
WO-2005016935-A2 REGIOSELECTIVE SYNTHESIS OF CCI-779 WYETH (US) 2005-02-24 WO claimed
EP-1064285-B1 NOVEL CEPHALOTAXANE DERIVATIVES AND PROCESS FOR THEIR PREPARATION STRAGEN PHARMA SA (CH) 2005-02-16 EP claimed
US-20050033046-A1 Regioselective synthesis of CCI-779 WYETH 2005-02-10 US claimed
WO-2004018451-A1 PYRIDAZINONE-DERIVATIVES AS PDE4 INHIBITORS ALTANA PHARMA AG (DE) 2004-03-04 WO claimed
EP-1216251-B1 REGIOSELECTIVE SYNTHESIS OF RAPAMYCIN DERIVATIVES WYETH CORP (US) 2003-02-26 EP claimed
EP-1216251-A2 REGIOSELECTIVE SYNTHESIS OF RAPAMYCIN DERIVATIVES Wyeth (US) 2002-06-26 EP claimed
US-20010039338-A1 Regioselective synthesis of rapamycin derivatives AMERICAN HOME PRODUCTS CORPORATION (US) 2001-11-08 US claimed
WO-2001023395-A2 REGIOSELECTIVE SYNTHESIS OF RAPAMYCIN DERIVATIVES AMERICAN HOME PRODUCTS CORPORATION (US) 2001-04-05 WO claimed
US-4727079-A Brain-specific dopaminergic activity involving dihydropyridine carboxamides, dihydroquinoline and isoquinoline carboxamides UNIVERSITY OF FLORIDA (US) 1988-02-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010039338-A1 Regioselective synthesis of rapamycin derivatives RICTOR, MTOR, RPTOR ALDH1A1 4478/4885TSHR 2980/4885HSD17B10 1308/4885
US-20050033046-A1 Regioselective synthesis of CCI-779 CCR9, CCR7, CCL11 ALDH1A1 1415/4885TSHR 3793/4885HSD17B10 1437/4885
US-20170137469-A1 POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS VIP, PEPD, NRDC ALDH1A1 4861/4885TSHR 4543/4885HSD17B10 4287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.